STOCK TITAN

Lucid Diagnostics: Medicare pays $1.94K per test

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Lucid Diagnostics Inc. reported third-quarter 2026 results and a Medicare reimbursement milestone for EsoGuard. The company says Medicare beneficiaries nationwide now have fully reimbursed access. Lucid reported first Medicare payments in October at the established Clinical Laboratory Fee Schedule rate of $1,938.01 per test; payments are through claim-by-claim adjudication and independent of the pending MolDX Local Coverage Determination reconsideration. Lucid performed 2,871 EsoGuard tests in the quarter and reported more than 1,800 tests in October, a record monthly volume.

Revenue was $1.203 million for the quarter, compared with $1.211 million a year earlier. GAAP net loss was $6.677 million, versus $10.397 million. Non-GAAP adjusted loss was $10.599 million. Cash and cash equivalents were $18.0 million as of September 30, 2026; after quarter-end, the company closed a $15.0 million Series C Convertible Preferred Stock financing. Lucid also launched its first two U.S. Department of Veterans Affairs programs and said five Concert client health plans, including three previously reported, are expected to have formally adopted its coverage policy by year-end.

2 points · 1 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 0 points

How the balance works

Positive

  • Major pointMedicare claim payments began at $1,938.01 per test in October.
  • Moderate pointThird-quarter GAAP net loss was $6.677 million, versus $10.397 million a year earlier.

Negative

  • None.
Item 2.02 Results of Operations and Financial Condition Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 7.01 Regulation FD Disclosure Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Revenue $1.203 million Three months ended September 30, 2026; $1.211 million for the comparable 2025 period
GAAP net loss $6.677 million Three months ended September 30, 2026; $10.397 million for the comparable 2025 period
Non-GAAP adjusted loss $10.599 million Three months ended September 30, 2026; $10.300 million for the comparable 2025 period
Operating expenses $13.479 million Three months ended September 30, 2026
Cash and cash equivalents $18.0 million As of September 30, 2026
Clinical Laboratory Fee Schedule rate $1,938.01 per test Rate Lucid reported receiving for Medicare claims in October
EsoGuard tests performed 2,871 tests Third quarter of 2026
EsoGuard tests performed More than 1,800 tests October 2026; record monthly volume
Clinical Laboratory Fee Schedule regulatory
"at EsoGuard’s established Clinical Laboratory Fee Schedule rate"
A clinical laboratory fee schedule is a set list of prices that a payer—such as a government program or insurance company—will reimburse for specific lab tests and services. Think of it as a menu of allowed payments that determines how much labs can charge and get paid; changes to those prices directly affect a lab’s revenue, profit margins and investment prospects because lower rates squeeze earnings while higher rates improve cash flow.
claim-by-claim adjudication regulatory
"coverage through claim-by-claim adjudication"
MolDX Local Coverage Determination regulatory
"pending MolDX Local Coverage Determination reconsideration"
non-GAAP adjusted loss financial
"the Company’s non-GAAP adjusted loss"
Category III CPT code medical
"a new Category III CPT code for EsoCheck cell collection"
A Category III CPT code is a temporary billing code used by medical providers to report new, experimental or emerging procedures, technologies, or services that do not yet have a permanent billing code. It matters to investors because assignment of such a code signals early clinical or market adoption, provides a way to capture usage and potential reimbursement data, and can hint at future revenue growth or regulatory and payment uncertainty—much like a temporary SKU that lets a retailer track early demand for a new product.
Revenue $1.203 million Compared with $1.211 million for the three months ended September 30, 2025
GAAP net loss $6.677 million Compared with $10.397 million for the three months ended September 30, 2025
Operating expenses $13.479 million Compared with $12.970 million for the three months ended September 30, 2025
Non-GAAP adjusted loss $10.599 million Compared with $10.300 million for the three months ended September 30, 2025

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What were LUCD’s third-quarter 2026 revenue and net loss?

LUCD reported revenue of $1.203 million and GAAP net loss of $6.677 million for the three months ended September 30, 2026. Revenue was $1.211 million and net loss was $10.397 million in the comparable 2025 quarter.

How much does Medicare pay for an EsoGuard test?

Lucid said Medicare beneficiaries nationwide now have fully reimbursed access to EsoGuard. It reported first Medicare payments in October on claims at the established Clinical Laboratory Fee Schedule rate of $1,938.01 per test, through claim-by-claim adjudication independent of the pending MolDX LCD reconsideration.

What were the results of Lucid’s 11,991-patient EsoGuard study?

Lucid reported successful EsoCheck sampling in 95% of patients in its 11,991-patient real-world study. Sampling averaged less than two minutes; the procedure was described as well tolerated, with no reported device-related adverse events and consistent performance across operators, including newly trained personnel.

When does Lucid expect the draft MolDX LCD to be published?

Lucid said it expects the draft LCD to be published as the administrative backlog begins to clear. The company reported holding a formal meeting with CMS leadership about the pending reconsideration and said the discussion reinforced its confidence that the delay is attributable to that backlog.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false 0001799011 0001799011 2026-11-12 2026-11-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): November 12, 2026

 

LUCID DIAGNOSTICS INC.
(Exact Name of Registrant as Specified in Charter)

 

Delaware   001-40901   82-5488042

(State or Other Jurisdiction

of Incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

360 Madison Avenue, 25th Floor, New York, New York   10017
(Address of Principal Executive Offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (917) 813-1828

 

N/A
(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, Par Value $0.001 Per Share   LUCD   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 
 

 

Item 2.02 Results of Operations and Financial Condition.

 

On November 12, 2026, Lucid Diagnostics Inc. (the “Company”) issued a press release announcing financial results for its fiscal quarter ended September 30, 2026 and providing a business update. A copy of the press release is attached to this report as Exhibit 99.1 and is incorporated herein by reference.

 

Item 7.01. Regulation FD Disclosure.

 

The disclosure set forth under Item 2.02 is incorporated herein by reference.

 

The information furnished under Items 2.02 and 7.01, including the exhibit related thereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any disclosure document of the Company, except as shall be expressly set forth by specific reference in such document.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits:

 

Exhibit No.   Description
99.1   Press release.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

2
 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: November 12, 2026 LUCID DIAGNOSTICS INC.
     
  By: /s/ Dennis McGrath
    Dennis McGrath
    Chief Financial Officer

 

3

 

 

Exhibit 99.1

 

Lucid Diagnostics Provides Business Update and Reports Third Quarter 2026 Financial Results

 

EsoGuard® now fully reimbursed by Medicare nationwide, launching a new phase of accelerating commercialization with record monthly test volume to start the fourth quarter

 

Conference call and webcast to be held today, November 12, at 8:30 AM EST

 

NEW YORK, November 12, 2026 - Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid” or the “Company”), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM) (“PAVmed”), today provided a business update and reported financial results for the third quarter ended September 30, 2026.

 

Conference Call and Webcast

 

The webcast will take place on Thursday, November 12, 2026, at 8:30 AM EST and will be accessible in the investor relations section of the Company’s website at luciddx.com. Alternatively, to access the conference call by telephone, U.S.-based callers should dial 1-800-836-8184 and international listeners should dial 1-646-357-8785. All listeners should provide the operator with the conference call name “Lucid Diagnostics Business Update” to join.

 

Following the conclusion of the conference call, a replay will be available for 30 days in the investor relations section of the Company’s website at luciddx.com.

 

Business Highlights

 

“Medicare is now paying for EsoGuard. For the first time, Medicare beneficiaries nationwide have fully reimbursed access to this groundbreaking test,” said Lishan Aklog, M.D., Lucid’s Chairman and Chief Executive Officer. “This breakthrough represents a seminal moment in our mission to end the scourge of esophageal cancer and marks the start of a new phase for Lucid focused on commercial acceleration and revenue growth.”

 

“Our pursuit of EsoGuard’s enormous clinical and commercial opportunity is now substantially less constrained by external factors,” Dr. Aklog added. “Lucid’s near-term growth now depends almost entirely on our team’s commercial and operational execution. Just a few weeks into this new chapter, our team delivered record monthly test volume in October and is approaching this opportunity with the urgency and determination it deserves. We are laser-focused on expanding access to EsoGuard for Medicare beneficiaries and translating this early momentum into revenue growth. What has been a marathon is now a sprint.”

 

 
 

 

Highlights from the third quarter and recent weeks:

 

●Received first Medicare payments for the EsoGuard® Esophageal DNA Test in October. Lucid began submitting claims in late September after meeting with medical directors at Novitas, the Medicare Administrative Contractor (MAC) with jurisdiction over Lucid’s Texas laboratory, and providing a clinical evidence dossier incorporating their feedback. Lucid has consistently received payments on these claims at EsoGuard’s established Clinical Laboratory Fee Schedule rate of $1,938.01 per test. This Medicare coverage through claim-by-claim adjudication is independent of the pending MolDX Local Coverage Determination (LCD) reconsideration for EsoGuard.
●Immediately and aggressively repositioned commercial efforts to expand EsoGuard testing among at-risk Medicare beneficiaries, representing approximately half of the patients recommended for esophageal precancer testing by professional society guidelines.
●Performed 2,871 EsoGuard tests and recognized revenue of $1.2 million in 3Q26. October was a record month for EsoGuard test volume, with more than 1,800 tests. More than 50,000 EsoGuard tests have been performed since launch.
●Held a formal meeting with CMS leadership on the pending MolDX LCD reconsideration for EsoGuard. The discussion reinforced Lucid’s confidence that the delay is attributable to an administrative backlog. Lucid expects the draft LCD to be published as that backlog begins to clear.
●Continued to expand commercial coverage through the Concert EsoGuard coverage policy, with a total of five Concert client health plans, including the three previously reported, expected to have formally adopted it by year-end.
●Launched Lucid’s first two U.S. Department of Veterans Affairs (VA) programs, with a robust pipeline of additional VA centers behind them. Lucid continues to expect the VA to be a meaningful long-term contributor to its commercial activity and revenue.
●Announced billing and coding milestones, including a new Category III CPT code for EsoCheck cell collection and a proposed ICD-10 diagnosis code for positive EsoGuard results, which will make EsoGuard and EsoCheck easier to bill, track and integrate into clinical practice.
●Announced publication of an 11,991-patient real-world EsoGuard study, the largest peer-reviewed study of nonendoscopic esophageal precancer testing to date. Sampling with the EsoCheck® Esophageal Cell Collection Device was successful in 95% of patients and averaged less than two minutes. The procedure was well tolerated, with no reported device-related adverse events and consistent performance across operators, including newly trained personnel.
●The American Gastroenterological Association (AGA) released its draft Barrett’s esophagus guidelines for public comment. The draft names EsoGuard and EsoCheck as an alternative to endoscopy, with high certainty of evidence. EsoGuard is the only commercially available test cited.
●Strengthened balance sheet with a $15.0 million private placement to existing long-term investors.

 

Financial Results

 

●For the three months ended September 30, 2026, EsoGuard related revenues were $1.2 million. Operating expenses were approximately $13.5 million, which included stock-based compensation expenses of $1.5 million. GAAP net loss attributable to common stockholders was approximately $6.7 million, or $(0.03) per common share.
●As shown below and for the purpose of illustrating the effect of stock-based compensation and other non-cash income and expenses on the Company’s financial results, the Company’s non-GAAP adjusted loss for the three months ended September 30, 2026 was approximately $10.6 million or $(0.06) per common share.
●Lucid had cash and cash equivalents of $18.0 million as of September 30, 2026, compared to $34.7 million as of December 31, 2025. Subsequent to quarter end, Lucid closed a $15.0 million Series C Convertible Preferred Stock financing.
●The unaudited financial results for the three and nine months ended September 30, 2026, were filed with the SEC on Form 10-Q on November 12, 2026, and available at www.luciddx.com or www.sec.gov.

 

 
 

 

Lucid Non-GAAP Measures

 

  ● To supplement our unaudited financial results presented in accordance with U.S. generally accepted accounting principles (GAAP), management provides certain non-GAAP financial measures of the Company’s financial results. These non-GAAP financial measures include net loss before interest, taxes, depreciation, and amortization (EBITDA), and non-GAAP adjusted loss, which further adjusts EBITDA for stock-based compensation expense and other non-cash income and expenses, if any. The foregoing non-GAAP financial measures of EBITDA and non-GAAP adjusted loss are not recognized terms under U.S. GAAP.
  ● Non-GAAP financial measures are presented with the intent of providing greater transparency to the information used by us in our financial performance analysis and operational decision-making. We believe these non-GAAP financial measures provide meaningful information to assist investors, shareholders, and other readers of our unaudited financial statements in making comparisons to our historical financial results and analyzing the underlying performance of our results of operations. These non-GAAP financial measures are not intended to be, and should not be, a substitute for, considered superior to, considered separately from, or as an alternative to, the most directly comparable GAAP financial measures.
  ● Non-GAAP financial measures are provided to enhance readers’ overall understanding of our current financial results and to provide further information for comparative purposes. Management believes the non-GAAP financial measures provide useful information to management and investors by isolating certain expenses, gains, and losses that may not be indicative of our core operating results and business outlook. Specifically, the non-GAAP financial measures include non-GAAP adjusted loss, and its presentation is intended to help the reader understand the effect of the loss on the issuance or modification of convertible securities, the periodic change in fair value of convertible securities, the loss on debt extinguishment, and the corresponding accounting for non-cash charges on financial performance. In addition, management believes non-GAAP financial measures enhance the comparability of results against prior periods.
  ● A reconciliation to the most directly comparable GAAP measure of all non-GAAP financial measures included in this press release for the three and nine months ended September 30, 2026, and 2025 are as follows:

 

(in thousands except per-share amounts)  For the three months ended
September 30,
   For the nine months ended
September 30,
 
   2026   2025   2026   2025 
                 
Revenue  $1,203   $1,211   $3,932   $3,202 
                     
Operating expenses   13,479    12,970    41,122    38,831 
Other (Income) expense, net   (5,599)   (1,362)   (4,917)   6,115 
Net Loss   (6,677)   (10,397)   (32,273)   (41,744)
Net income (loss) per common share, basic and diluted  $(0.03)  $(0.10)  $(0.26)  $(0.59)
Net loss attributable to common stockholders   (6,677)   (10,397)   (45,020)   (54,303)
Preferred Stock dividends and deemed dividends   —    —    12,747    12,559 
Net income (loss) as reported   (6,677)   (10,397)   (32,273)   (41,744)
Adjustments:                    
Depreciation and amortization expense1   226    220    671    663 
Interest expense, net2   (58)   (99)   (195)   (260)
EBITDA   (6,509)   (10,276)   (31,797)   (41,341)
                     
Other non-cash or financing related expenses:                    
Stock-based compensation expense3   1,451    1,152    4,555    3,326 
Operating expenses issued in stock1   —    87    57    234 
Change in FV convertible debt2   (5,541)   (2,341)   (4,722)   5,297 
Equity issuance cost extinguishment2   —    1,078    —    1,078 
Non-GAAP adjusted (loss)  $(10,599)  $(10,300)  $(31,907)  $(31,406)
Basic and Diluted shares outstanding   190,945    108,176    171,575    92,131 
Non-GAAP adjusted (loss) income per share  $(0.06)  $(0.10)  $(0.19)  $(0.34)

 

1 Included in general and administrative expenses in the financial statements.

 

2 Included in other income and expenses.

 

3 Stock-based compensation (“SBC”) expense included in operating expenses is detailed as follows in the table below by category within operating expenses for the non-GAAP Net operating expenses:

 

 
 

 

(in thousands except per-share amounts)  For the three months ended
September 30,
   For the nine months ended
September 30,
 
   2026   2025   2026   2025 
Cost of revenues  $1,404   $1,697   $4,474   $4,810 
Stock-based compensation expense3   (14)   (43)   (142)   (152)
Net cost of revenues   1,390    1,654    4,332    4,658 
                     
Amortization of intangible assets   105    105    315    316 
                     
Sales and marketing   5,252    4,291    16,029    12,367 
Stock-based compensation expense3   (314)   (268)   (907)   (753)
Net sales and marketing   4,938    4,023    15,122    11,614 
                     
General and administrative   5,536    5,605    16,723    17,383 
Depreciation expense   (121)   (115)   (356)   (347)
Operating expenses issued in stock   —    (87)   (57)   (234)
Stock-based compensation expense3   (949)   (718)   (3,024)   (2,060)
Net general and administrative   4,466    4,685    13,286    14,742 
                     
Research and development   1,182    1,272    3,581    3,955 
Stock-based compensation expense3   (174)   (123)   (482)   (361)
Net research and development   1,008    1,149    3,099    3,594 
                     
Total operating expenses   13,479    12,970    41,122    38,831 
Depreciation and amortization expense   (226)   (220)   (671)   (663)
Operating expenses issued in stock   —    (87)   (57)   (234)
Stock-based compensation expense3   (1,451)   (1,152)   (4,555)   (3,326)
Net operating expenses  $11,802   $11,511   $35,839   $34,608 

 

About Lucid Diagnostics

 

Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. Lucid is focused on the millions of patients with GERD, also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid’s EsoGuard® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck® Esophageal Cell Collection Device - the first and only commercially available tools designed with the goal of preventing esophageal cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients.

 

For more information, please visit luciddx.com and for more information about its parent company PAVmed, please visit pavmed.com.

 

Forward-Looking Statements

 

This press release includes forward-looking statements that involve risk and uncertainties. Forward-looking statements are any statements that are not historical facts. Such forward-looking statements, which are based upon the current beliefs and expectations of Lucid Diagnostics’ management, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. Risks and uncertainties that may cause such differences include, among other things, volatility in the price of Lucid Diagnostics’ common stock; general economic and market conditions; the uncertainties inherent in research and development, including the cost and time required to advance Lucid Diagnostics’ products to regulatory submission; whether regulatory authorities will be satisfied with the design of and results from Lucid Diagnostics’ clinical and preclinical studies; whether and when Lucid Diagnostics’ products are cleared by regulatory authorities; market acceptance of Lucid Diagnostics’ products once cleared and commercialized; Lucid Diagnostics’ ability to raise additional funding as needed; and other competitive developments. These factors are difficult or impossible to predict accurately and many of them are beyond Lucid Diagnostics’ control. In addition, new risks and uncertainties may arise from time to time and are difficult to predict. For a further list and description of these and other important risks and uncertainties that may affect Lucid Diagnostics’ future operations, see Part I, Item 1A, “Risk Factors,” in Lucid Diagnostics’ most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as the same may be updated in Part II, Item 1A, “Risk Factors” in any Quarterly Report on Form 10-Q filed by Lucid Diagnostics after its most recent Annual Report. Lucid Diagnostics disclaims any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in its expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.

 

Investor and Media Contact

 

Matt Riley

Vice President, Investor Relations

PAVmed and Lucid Diagnostics
mjr@pavmed.com

 

 

 

Filing Exhibits & Attachments

4 documents

Keep reading